Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...

Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...

Please provide your email address to receive an email when new articles are posted on . In a first-in-human phase 1/2 study, GT005, an AAV2-based one-time investigational gene therapy, showed ...

The complement pathway is a regulated cascade of proteins that supports or complements (hence the name) the activity of antibodies and phagocytes in clearing infections. The pathway comprises three ...

- Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020 ...

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs. The company's unique approach of ...